Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Combination use can lead to rare condition of muscle damage
The FDA is notifying the public of an increased risk of muscle breakdown (rhabdomyolysis) when the cholesterol-lowering medication simvastatin (marketed as Zocor and generics), Ezetimibe/Simvastatin (marketed as Vytorin), or Niacin Extended-Release /Simvastatin (marketed as Simcor), is used with amiodarone (Cordarone, Pacerone), a drug used for abnormal heart rhythms. Rhabdomyolysis is a rare condition which can lead to kidney failure if not detected early. This risk is dose-related and increases when a dose of simvastatin greater than 20 mg per day is given with amiodarone. For more information, please visit: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm118869.htm
Learn More

Combination use can lead to rare condition of muscle damage
The FDA is notifying the public of an increased risk of muscle breakdown (rhabdomyolysis) when the cholesterol-lowering medication simvastatin (marketed as Zocor and generics), Ezetimibe/Simvastatin (marketed as Vytorin), or Niacin Extended-Release /Simvastatin (marketed as Simcor), is used with amiodarone (Cordarone, Pacerone), a drug used for abnormal heart rhythms. Rhabdomyolysis is a rare condition which can lead to kidney failure if not detected early. This risk is dose-related and increases when a dose of simvastatin greater than 20 mg per day is given with amiodarone. For more information, please visit: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm118869.htm
Learn More

Date Published Title Drug Source
2008-08-08 Combination use can lead to rare condition of muscle damage Simvastatin FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Amiodarone FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Lovastatin FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Atorvastatin FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Ezetimibe with Simvastatin FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Atorvastatin and Amlodipine FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Lovastatin and Niacin FDA
2008-08-05 Generic Manufacturer Recalls Several Drug Products Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Chlordiazepoxide with Clidinium Bromide Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Carisoprodol with Aspirin Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Soma Compound with Codeine Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Sodium Fluoride Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Multivitamin Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Vitaplex Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Vitaplex Comp Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Vitamin K Manufacturer
2008-08-04 Generic Manufacturer Recalls Several Drug Products Amantadine Manufacturer
2008-08-04 Generic Manufacturer Recalls Several Drug Products Manufacturer
Back to Consumer Med Safety